Pavurutamab  (Synonyms: AMG-701)

Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM)^[1][2][3][4].

(scFv-heavy-kappa)-(scFv-heavy-lambda)-scFc

Human IgG1 kappa, Isotype Control

Human

CD3E & TNFRSF17

Pavurutamab (0-10000 pM; 48 h) induces CD69⁺, CD25⁺ T cell activation and IFNγ, TNFα, IL-2, IL-4, IL-6, IL-10 cytokine secretion^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pavurutamab (0.02, 0.2 and 2 mg/kg; i.v.; single dose on days 3, 8, 13) reduces tumor volume with time and dose dependent manner in mouse xenograft models^[5].
Pavurutamab (0.005, 0.05 and 0.5 mg/kg; i.v.; every 5 days for 6 administrations, lasting for 30 days) reduces tumor volume and increases survival with time and dose dependent manner in NOD/SCID mice transplanted with L-363 multiple myeloma (MM) cells^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

916  [NCBI] & 608  [NCBI]

P07766 & Q02223

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

105.78 kDa

2250292-39-6

Liquid

Colorless to light yellow

[Pavurutamab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  (scFv-heavy-kappa)-(scFv-heavy-lambda)-scFc

• 
  Immobilized Pavurutamab can bind Human CD3 epsilon/CD3e Protein (ECD, His Tag). The EC₅₀ for this effect is 1.26 ng/mL.
• 
  Immobilized Pavurutamab can bind Human BCMA Protein (ECD, His Tag). The EC₅₀ for this effect is 0.194 ng/mL.
• 
  Flow cytometric analysis of 1×10⁶ Jurkat cells labelling CD3E (red) with Pavurutamab (HY-P99814). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control.

• [1]. Sheridan C. Bispecific antibodies poised to deliver wave of cancer therapies. Nat Biotechnol. 2021 Mar;39(3):251-254.  [Content Brief]

  [2]. Goldsmith SR, et al. Bispecific Antibodies for the Treatment of Multiple Myeloma. Curr Hematol Malig Rep. 2022 Dec;17(6):286-297.  [Content Brief]

  [3]. Cho SF, et al. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020 Sep 8;4(17):4195-4207.  [Content Brief]

  [4]. Harrison S J, et al. A phase 1 first in human (FIH) study of AMG 701, an anti-B-cell maturation antigen (BCMA) half-life extended (HLE) BiTE®(bispecific T-cell engager) molecule, in relapsed/refractory (RR) multiple myeloma (MM)[J]. Blood, 2020, 136: 28-29.

  [5]. Goldstein RL, et al. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. Blood Adv. 2020 Sep 8;4(17):4180-4194.  [Content Brief]